QUINCE THERAPEUTICS INC (QNCX)
US22053A1079 - Common Stock
| MRQ (2024-9-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | 1.68M | 1.52M | 4.00M | 40.30M | 35.70M | |||
| Cash Equivalents | 997.00K | 4.29M | 11.00M | 16.00M | 16.20M | |||
| Marketable Securities | 45.17M | 69.25M | 75.20M | 50.60M | 82.00M | |||
| Other Current Assets | 3.87M | 2.38M | 3.60M | 4.90M | 4.00M | |||
| Total Current Assets | 51.72M | 77.44M | 93.70M | 111.70M | 137.90M | |||
| Non-Current Assets | ||||||||
| PPE Net | 767.00K | 619.00K | 700.00K | 1.40M | 1.10M | |||
| Investments And Advances | 78.00K | 78.00K | 3.60M | 19.90M | 50.50M | |||
| Goodwill | 0.00 | 17.63M | N/A | N/A | N/A | |||
| Intangibles | 64.53M | 63.67M | 5.90M | N/A | N/A | |||
| Other Non-Current Assets | 4.07M | 8.47M | 0.00 | 200.00K | 0.00 | |||
| Total Non-Current Assets | 74.80M | 90.46M | 10.20M | 21.50M | 51.60M | |||
| TOTAL ASSETS | 126.52M | 167.90M | 103.90M | 133.20M | 189.50M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | N/A | 0.00 | 100.00K | N/A | N/A | |||
| Accrued Expenses | 3.80M | 3.44M | 2.40M | 9.30M | 13.40M | |||
| Accounts Payable | 1.62M | 2.03M | 600.00K | 4.90M | 3.60M | |||
| Other Current Liabilities | 0.00 | 4.10M | N/A | N/A | N/A | |||
| Total Current Liabilities | 5.42M | 9.57M | 3.10M | 14.20M | 17.00M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 14.90M | 13.43M | 0.00 | 0.00 | 0.00 | |||
| Deferred Taxes/Income | 5.38M | 5.30M | 200.00K | N/A | N/A | |||
| Other Non-Current Liabilities | 55.88M | 54.51M | 0.00 | 400.00K | 200.00K | |||
| Total Non-Current Liabilities | 76.16M | 73.24M | 200.00K | 400.00K | 200.00K | |||
| TOTAL LIABILITIES | 81.59M | 82.82M | 3.30M | 14.60M | 17.20M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -364.01M | -319.64M | -288.30M | -236.60M | -146.70M | |||
| Additional Paid In Capital | 405.48M | 401.64M | 389.10M | 355.20M | 318.60M | |||
| Common Shares | 43.00K | 43.00K | 0.00 | 0.00 | 0.00 | |||
| Other Shareholders' Equity | 3.42M | 3.05M | -300.00K | -100.00K | 300.00K | |||
| Shares Outstanding | 43.28M | 42.97M | 36.10M | 30.10M | 29.50M | |||
| Tangible Book Value per Share | -0.45 | 0.09 | 2.62 | 3.94 | 5.84 | |||
| Total Shareholders' Equity | 44.93M | 85.08M | 100.60M | 118.60M | 172.30M | |||
| TOTAL LIABILITIES AND EQUITY | 126.52M | 167.90M | 103.90M | 133.20M | 189.50M | |||
| Statistics | ||||||||
| Debt/Equity | 0.33 | 0.16 | N/A | N/A | N/A | |||
| Current Ratio | 9.53 | 8.09 | 30.23 | 7.87 | 8.11 | |||
| Return On Assets (ROA) | -42.10% | -18.69% | -49.72% | -67.53% | -40.55% | |||
| Return On Equity (ROE) | -118.54% | -36.89% | -51.35% | -75.84% | -44.60% | |||
All data in USD , ROIC based on taxRate of 0.21